The Cigna

Cigna Group Poised for Growth with Integrated Care and Pharmacy Services

Cigna Group: Mixed Returns and Undervaluation Amidst Low P/E Multiple

Is Unum Group's Recent Share Price Attractive After a Three-Year Tripling?

信诺保险

Cigna's 15min chart triggers Bollinger Bands Expanding Upward, KDJ Golden Cross

Cigna Group Named Top Socially Responsible Dividend Stock with 2.2% Yield

Catalyst<ul> <li>Most analysts rate CI Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Bearish signals are obviously dominant (2 bearish vs 0 bullish) according to technical indicators.</li> <li>Fund flows are negative across all order sizes, indicating outflows from the stock.</li></ul>

Key Factors

Cigna's (CI) shares closed nearly 3% higher following President Trump's healthcare plan announcement, as investors interpreted the policy as favorable for the insurance sector. Mizuho analyst Ann Hynes upgraded Cigna's (CI) price target to $325 from $307, maintaining a Buy rating, citing growth through integrated care and pharmacy services. Cigna (CI) is targeting a $1.5 trillion specialty drug market, leveraging its integrated care platform to capture value from high-cost drug growth and expanding pharmacy services.

CI News